InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,018.39
(
-0.34%
)
US TECH 100
16,925.60
(
-0.34%
)
Dow Jones
37,903.29
(
0.23%
)
Brent Oil
83.54
(
-2.74%
)
Bitcoin
57,984.72
(
-4.32%
)
Post# of 251670
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 827
Posts 119535
Boards Moderated 15
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 100528

Tuesday, 08/03/2010 12:21:52 PM

Tuesday, August 03, 2010 12:21:52 PM

Post# of 251670

The prevalence of the EML4-ALK fusion oncogene is higher among lung adenocarcinomas, in non or light smokers, and in EGFR, KRAS-negative cases.

Are there significant commercial ramifications associated with this observation (apart from the raw frequency of the variant)? T.i.a.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up